Shots:

• The companies enter into a research collaboration to utilize Insilico’s ML technology and Pandomics discovery platform with the focus to identify real-world evidence for potential therapeutic targets for multiple diseases
• The collaboration allows Insilico to advance its target identification system utilizing ML- generative biology methods and synthetic data generation pipelines
• The agreement enables Pfizer to explore new technologies that aid in identifying targets and biomarkers- leading to breakthrough therapies targeting unmet medical needs

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Alberamonti